United Kingdom Daily Briefing

Tehran is now conditioning any Strait of Hormuz reopening on the US correcting its behaviour, and the UAE confirmed one of its ships took an Iranian missile hit — this is not the environment for a near-term resolution. BP -1.42% and Shell -1.23% today price simultaneous supply disruption risk and throughput uncertainty rather than a clean oil-price tailwind. For FTSE 100, the maths is awkward: higher Brent should be a net positive given the index's energy weighting, but constrained Hormuz shipping capacity complicates upstream production economics for integrated majors. If the situation escalates over the weekend, BP and Shell open Monday as binary reads — and gilt yields will have to absorb any renewed inflation anxiety from an energy-price spike that BoE did not need going into the August CPI print.

Mike Ashley's characterisation of Harvey Nichols as being in a death spiral crystallises a structural problem that goes well beyond one retailer: post-pandemic footfall has not recovered to the level needed to sustain the occupancy costs and staffing ratios that luxury-tier curated retail requires. The proposed fix — refocusing on design curation over volume — is a multi-year margin rebuilding story with no immediate catalyst visible. For FTSE 250 watchers, this is a sector-level signal: consumer discretionary closed +1.25% Friday, but that resilience looks fragile against the Harvey Nichols read. The UK consumer is still navigating Bank Rate at 4.5% — discretionary spend at the luxury end remains under structural compression, and department stores are the most exposed format.

Berkshire Hathaway Q2 marked the first net equity purchase in over three years — $20bn net into stocks under Greg Abel's first major capital deployment as chief executive. The signal is global but reads directly for UK equity holders: the world's most famously patient capital is done sitting in T-bills. For FTSE 100, the parallel argument runs through dividend yield: FTSE 100's historically 4% yield looks compelling in an environment where disciplined capital allocators are rotating back to equities. GSK +1.51% today, AZN positioned for the week ahead — quality FTSE 100 names sit well in this framing. The UK market's persistent discount to the S&P 500 starts to look more like an opportunity than a structural fact when yield-seeking global capital returns to work.